Histone Deacetylase Inhibitors: Can We Consider Potent Anti-Neoplastic Agents for the Treatment of Asthma?
Simon G Royce, Katherine Ververis, Tom C Karagiannis
ANNALS OF CLINICAL AND LABORATORY SCIENCE | ASSOC CLINICAL SCIENTISTS | Published : 2012
Histone deacetylase inhibitors have emerged as a new class of anti-cancer therapeutics due to their potent anti-proliferative and apoptotic effects in malignant cells. Accumulating evidence is indicating that histone deacetylase inhibitors may also have potential clinical utility in non-oncological applications, including asthma. However, the potential of histone deacetylase inhibitors in asthma remains controversial. For example, the mechanisms of action of the broad-spectrum histone deacetylase inhibitor, Trichostatin A, in animal models of allergic airways disease are conflicting. Further, there is evidence suggesting potential problems associated with histone deacetylase 2 inhibition and..View full abstract
The support of the Australian Institute of Nuclear Science and Engineering is acknowledged. TCK was the recipient of AINSE awards. Epigenomic Medicine Laboratory is supported by the National Health and Medical Research Council of Australia. KV is supported by a Baker IDI post-graduate scholarship. Supported in part by the Victorian Government's Operational Infrastructure Support Program. All of the authors (SCR, KV and TCK) declare that they have no direct financial relation with the commercial identities mentioned in this manuscript that might lead to a conflict of interest.